Outlook Therapeutics SG&A Expense (Quarterly) Analysis

Outlook Therapeutics Inc (OTLK)

8.35 -0.16 (-1.88%) USD | NASDAQ | May 02, 10:35

SG&A Expense (Quarterly) Chart

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2014. Upgrade now.

Date	Value
December 31, 2023	5.794M
September 30, 2023	7.515M
June 30, 2023	7.040M
March 31, 2023	6.293M
December 31, 2022	5.826M
September 30, 2022	4.998M
June 30, 2022	5.775M
March 31, 2022	6.690M
December 31, 2021	3.277M
September 30, 2021	3.501M
June 30, 2021	2.930M
March 31, 2021	4.096M
December 31, 2020	2.242M
September 30, 2020	2.390M
June 30, 2020	3.287M
March 31, 2020	1.957M
December 31, 2019	2.337M
September 30, 2019	2.782M
June 30, 2019	1.834M

Date	Value
March 31, 2019	1.849M
December 31, 2018	2.904M
September 30, 2018	6.036M
June 30, 2018	2.196M
March 31, 2018	2.446M
December 31, 2017	3.549M
September 30, 2017	3.508M
June 30, 2017	3.482M
March 31, 2017	4.024M
December 31, 2016	4.871M
September 30, 2016	6.574M
June 30, 2016	10.50M
March 31, 2016	-0.1894M
December 31, 2015	4.674M
September 30, 2015	4.666M
June 30, 2015	2.660M
March 31, 2015	4.342M
December 31, 2014	1.238M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

1.834M

Minimum

Jun 2019

7.515M

Maximum

Sep 2023

4.240M

Average

3.501M

Median

Sep 2021

SG&A Expense (Quarterly) Benchmarks